Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ALKS 2680 in adults with Narcolepsy Type 1, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy Type

Drugs mentioned

• ALKS 2680

Snippet

Sponsor: Alkermes, Inc. | Conditions: Narcolepsy Type 1 | Phase 3 | Status: NOT_YET_RECRUITING